Sanofi-Aventis May Prolong Offer For US Genzyme
From M&A Navigator (January 20, 2011)
French drug producer Sanofi-Aventis (EPA:SAN) is expected to once
again extend the deadline of its USD69 (EUR51.19) per share offer
for US biotech firm Genzyme (NASDAQ:GENZ), Reuters reported,
quoting sources in the know.
The offer, which evaluates Genzyme at USD18.5bn, ends this Friday. Sanofi-Aventis already extended its proposal in December when it had secured a mere 1% of the US company stock.
Now the two companies have entered direct talks and an extension is seen as a formality to enable the possible recommendation of the offer to the Genzyme's shareholders, Reuters said. Investors even see an increase of the offer towards USD80 per share, the agency added.
The two sides have considerably advanced in the negotiations, a source told the news agency.
Country: , USA
Sector: Pharmaceuticals, Biotechnology
Target: Genzyme Corporation
Buyer: Sanofi-Aventis SA
Deal size in USD: 18.5bn
Type: Corporate acquisition
Status: Bidding
Comment: Offer may be extended.
((Comments on this story may be sent to info@m2.com))
Posted: January 2011
